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Abbreviations 
CMAP: compound muscle action potential 
DM1: Myotonic dystrophy type 1 
DM2: Myotonic dystrophy type 2 
DMPK: Dystrophia myotonica – Protein kinase 
ESN: early supernormality 
ISI: inter-stimulus interval 
LSN: late  supernormality 
MC: myotonia congenita 
MRRP: muscle relative refractory period 
MSN: mean supernormality  
MVRC: muscle velocity recovery cycle 
RSN: residual supernormality 
SET: short exercise test 
SN20(%): Supernormality at 20ms (mean of supernormalities at 18 and 22 ms)  
TA: tibialis anterior 
5ESN: early supernormality after 5 conditioning stimuli 
5SN20(%): Supernormality at 20ms after 5 conditional stimuli. 
5XLSN: extra late supernormality after 5 conditioning pulses (similarly, 5XRSN). 
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ABSTRACT   (Max 150 words) 
 
Introduction:  Myotonia in myotonic dystrophy types 1 (DM1) and 2 (DM2) is 
generally attributed to reduced chloride channel conductance. We used muscle 
velocity recovery cycles (MVRCs) to investigate muscle membrane properties in 
DM1 and DM2, with comparisons with myotonia congenita (MC).  
Methods:  MVRCs and responses to repetitive stimulation were compared between 
patients with DM1 (n=18), DM2 (n=5), MC (n=18), and normal controls (n=20).  
Results:  Both DM1 and DM2 showed enhanced late supernormality after multiple 
conditioning stimuli, indicating delayed repolarization as in MC. Contrary to MC, 
however, DM1 showed reduced early supernormality after multiple conditioning 
stimuli, and weak DM1 patients also showed abnormally slow latency recovery after 
repetitive stimulation.   
 Discussion:  These findings support impaired chloride conductance in both DM1 and 
DM2. The early supernormality changes indicate that sodium currents were reduced 
in DM1, while the weakness-associated slow recovery after repetitive stimulation may 
provide an indication of reduced Na
+
/K
+
-ATPase activation.  
 
 
  
 
Page 4 of 32
John Wiley & Sons, Inc.
Muscle & Nerve
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
 55 
INTRODUCTION 
Myotonic dystrophy (DM1) is the most common muscular dystrophy in adults. 
It is caused by the expansion of an unstable trinucleotide (CTG)n repeat in an 
untranslated, but transcribed, portion of the 3’ region of the DM1 protein kinase 
(DMPK) gene on chromosome 19q13.3
1
 . 
The main mechanisms currently thought to underlie the multisystemic 
abnormalities in DM1 can be divided into: (a) a gain-of-function  effect leading to 
RNA toxicity due to the transcribed mutant DMPK mRNA affecting RNA splicing 
factors, resulting in abnormal splicing of mRNA transcripts of various proteins 
[including the muscle chloride ion channel (CLC-1)]; (b) altered expression of 
neighboring genes such as SIX5 (causing cataracts); and (c) abnormalities in the 
structure, enzymatic activity, and subcellular localization of the DMPK protein itself 
2-8
. 
In DM1, the myotonia is thought to arise due to misregulation of alternative 
splicing of the muscle chloride channel CLC-1
9,10
, together with transcriptional 
downregulation of CLCN1 due to leaching of the transcription factor SP1 by mutant 
RNA
11
. Less emphasis is given to the early suggestions that sodium channel 
dysfunction may be relevant to myotonia in DM1
2,3
.  
DMPK is a serine/threonine kinase and has been shown to modulate skeletal 
muscle Na
+ 
 channels
3,12
 and Ca
2+
 homeostasis
4
. Although there have been 
contradictory results about the effects of the DM1 mutation on the levels of DMPK 
mRNA and protein levels in patient tissues
13-16
, typically, muscle fibers and/or 
cultured skeletal muscle cells of DM patients exhibit a decreased resting membrane 
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potential
17-19
, and increased basal cytosolic Na
+
 and Ca
2+
 concentrations
20-22
, which 
are likely to be relevant to the muscle pathophysiology in DM1.  
Myotonic dystrophy type 2 (DM2), initially termed proximal myotonic 
myopathy, is caused by an unstable tetranucleotide (CCTG)n repeat expansion in the 
first intron of the cellular nucleic acid-binding protein (CNBP) gene on chromosome 
3q21.3 
23,24
. Although patients with DM2 have some clinical features in common with 
DM1 (such as myotonia, cataracts, and diabetes), there are significant differences, in 
that life expectancy is typically normal in DM2, muscle weakness is usually of late 
onset (50-70 years), there is no congenital form, muscle atrophy is rarely seen, and 
bulbar and respiratory weakness is exceptional
25
. As in DM1, the disruption in cellular 
function due to the pathogenic effects of the (CCUG)n RNA expansion are thought to 
underlie the multisystemic features in DM2, although there is evidence that CNBP 
haploinsufficiency in itself may account for many of the changes in skeletal and 
cardiac muscle. This includes the myotonia in DM2, which appears to be due to 
downregulation of CLC-1, secondary to low levels of CNPB, without mis-splicing of 
CLCN1 
26
. 
We have recently used muscle velocity recovery cycles (MVRCs) and a 
repetitive stimulation protocol to investigate how membrane function is affected in 
patients with myotonia congenita (MC), and found evidence of an enhanced 
depolarizing afterpotential, which was reduced in patients treated with Na
+ 
channel 
blockers. In addition, contrary to the widely held view that chloride conductance 
makes a large contribution to resting membrane conductance, we found that chloride 
conductance only became important when muscle fibers were depolarized
27
.  
In this study, we used the same protocol to investigate how membrane 
function is altered in DM1 and DM2 patients, with the aim of confirming the expected 
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reduction of chloride channel conductance, and to investigate whether there was 
evidence of concomitant sodium channel dysfunction in the DM1 patients. We 
compared the findings to those of MC patients, and to age-matched normal controls.  
 
METHODS 
Patients  
 
All 18 DM1 patients and 5 DM2 patients were genetically confirmed. The 
patients were aged 43.9 ± 15.1 years (mean ± SD), range 20-73 years (Table 1). There 
were 9 men and 14 women. Three patients (2 DM1, 1 DM2) were diabetic. Eighteen 
previously studied
27
 patients with genetically confirmed myotonia congenita (11 
ARMC, 7 ADMC) were included for comparison.  Eleven of these patients (6 ARMC, 
5 ADMC) were designated as ‘Rx-’ (i.e. these patients were either taking no 
medication for myotonia, or had omitted the medication for >5 times the half-life of 
the drug at the time of the study).  Another 7 MC patients (5 ARMC, 2 ADMC), were 
taking mexiletine or carbamazepine and were designated ‘Rx+’. 
 
Asymptomatic Controls  
The MVRC studies were compared with recordings from 20 healthy 
volunteers, 5 men, 15 women, aged 44.1 ± 13.3 years (range 27-69) who served as 
normal controls (NC). 
 
Consent 
Informed written consent was obtained from all patients and controls 
according to the Declaration of Helsinki. This study was approved by the St Thomas’ 
Hospital Research Ethics Committee, London, UK.   
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Study Protocol 
All the patients had standard nerve conduction studies, muscle velocity 
recovery studies, the short exercise test at room temperature, and a blood sample for 
electrolytes and glucose taken on the same day (within 2 hours of the studies). Ankle 
dorsiflexion power was graded (MRC scale) on the day of the study. 
 
Short Exercise Test 
 
Short exercise tests (SETs) were performed by stimulating the ulnar nerve at 
the wrist and recording with surface electrodes on abductor digiti minimi. Compound 
muscle action potentials (CMAPs) were recorded at baseline and every 10s during 3 
short exercise trials (10s exercise followed by 60s rest). The amplitude changes from 
baseline were calculated and plotted as described previously 
28
.  
 
Muscle velocity recordings  
Experimental setup 
The recording technique was as described previously for tibialis anterior (TA)
29,30,27
. 
Recordings were performed on the distal third of TA, with the monopolar stimulating 
needle inserted perpendicularly within 1 cm of the palpated distal extent of the 
muscle.  Stimulation currents were delivered through an insulated monopolar needle 
electrode (28G, TECA, Viasys Healthcare, Madison, Wisconsin, USA) inserted to a 
depth of 6-8 mm, while a non-polarizable surface electrode (Kendall Q-trace, Tyco 
Healthcare group, UK) placed distal and laterally on the muscle served as the anode. 
Rectangular pulses (0.05 ms) generated by a computer were converted to current with 
an isolated constant-current stimulator (DS5; Digitimer Ltd., Welwyn Garden City, 
Hertfordshire, UK). Muscle activity was recorded by means of a concentric needle 
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electrode (disposable 30G concentric EMG needle, Cardinal Health, Madison, 
Wisconsin, USA) approximately 20 mm proximal to the stimulating needle.  The 
ground electrode (Kendall, as above) was positioned between the stimulating and 
recording electrodes. Patients were seen in a heated room and kept warm in an effort 
to achieve a skin temperature as near as possible to 32 deg C at the start of the study. 
Surface temperature over TA was recorded at the end of the recording.  
The signal was amplified (gain 1000, bandwidth 0.2 Hz to 3 kHz) and 
digitized (NIDAQ-6062E, National Instruments Europe Corp., Debrecen, Hungary) 
using a sampling rate of 20 kHz. The electrodes were adjusted to obtain a stable 
negative peak response with a stimulus of 3-10 mA. Stimulation and recording were 
controlled by Qtrac software (written by H. Bostock, Institute of Neurology, London, 
UK), using the 1200RCMQ.QRP recording protocol. 
 
Muscle Velocity recovery cycles (MVRCs) at rest 
MVRCs were recorded with 1, 2, and 5 conditioning stimuli, all separated by 10 ms 
inter-stimulus intervals (ISI). Test stimuli were delivered every 2s. The ISI between 
the last conditioning stimulus and the test stimulus was varied from 1000 to 1.4 ms in 
34 steps in an approximately geometric series (specifically 1000, 900, 800, 700, 600, 
500, 450, 400, 350, 300, 260, 220, 180, 140, 110, 89, 71, 56, 45, 35, 28, 22, 18, 14, 
11, 8.9, 7.1, 5.6, 4.5, 3.5, 2.8, 2.2, 1.8 and 1.4 ms). 
Frequency ramp.   
To characterize the effects of progressive muscle activation, delivery of 1 
stimulus every 2 sec was replaced by a 1-sec train of stimuli delivered every 2 sec, 
with the number of stimuli in the train increased by 1 from 2 to 30 in successive 2-sec 
cycles (see Fig. 4 in Boerio et al., 2012)
29
. During the frequency ramp, the mean 
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stimulation rate increased from 1 to 15 Hz over 1 minute, and responses were 
measured to the first and last stimuli in each train.   Stimulus cycles with the test 
stimulus alone were recorded before the frequency ramp (10 cycles at 0.5Hz) and for 
30 sec after the end of the ramp.  
 
Data analysis 
 Recovery cycle data were analyzed by the QtracP program, as previously 
described
31
. The waveforms were first filtered with digital high pass (100 Hz cut-off) 
and low pass (500 Hz) filters applied both in forward and reverse time directions to 
provide baseline stabilization and smoothing without time displacement
32
. Response 
latencies were then measured from the start of the test stimulus to the negative peak of 
the muscle action potential. The effects of 1, 2, and 5 conditioning pulses on the 
latency of the test response were calculated as percentage differences compared to the 
test stimulus alone.  
Several excitability measures were derived from the 3 recording protocols: 
a) VRCs at rest. The MRRP was defined as the earliest (interpolated) ISI at 
which the latencies of the conditioned and unconditioned test responses were 
identical.  Early supernormality (ESN) was measured as the largest percentage 
decrease in latency for ISIs below 15 ms.  Late supernormality (LSN) was the mean 
percentage decrease in latency for ISIs between 50 and 150 ms.  We defined 
‘supernormality at 20 ms’ (SN20) as the mean of supernormalities at 18 and 22 ms, 
5ESN as the early supernormality after 5 conditioning impulses, and ‘residual 
supernormality’ (RSN) as the mean percentage decrease in latency at the end of the 
sweep, averaged for ISIs of 900 and 1000 ms. We also defined the ‘extra’ 
supernormalities 5XLSN and 5XRSN as the differences between the percentage 
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latency decreases for 5 and 1 conditioning stimuli.  Compared with previous MVRC 
studies, we additionally defined ‘supernormality to 5 conditioning stimuli at 20ms’ 
(5SN20) as the mean of supernormalities at 18 and 22ms to 5 conditioning stimuli. 
 b) Frequency ramp.  From the frequency ramp recordings we measured the 
latency of the negative peak of the muscle action potential, expressed as a percentage 
of baseline latency, at 15Hz [Lat(15Hz)] and 30Hz [Lat(30Hz)] during the ramp, and 
30s after the end of the ramp Lat(30Hz+30s)%.   During the ramp, responses to the 
first and last stimuli in the train were designated with the subscript First or Last 
respectively. 
 
Statistics 
Many of the activity-dependent conduction measures failed the Lilliefors test 
of normality, and because of the small sample size of the groups, for intergroup 
comparisons we used the Mann Whitney U test, and for correlations between 
measures we used the Spearman rho (ρ).  When comparing groups with multiple U-
tests or correlations, only P<0.01 was considered significant, but for discussion, 
P<0.05 is mentioned when relevant for individual tests.  
 
RESULTS 
 
MRC grading of Tibialis Anterior  
The strength of the relevant tibialis anterior muscle was graded (MRC scale) 
prior to the muscle excitability studies, and the results are shown in Table 1. For the 
purposes of comparing excitability data between weak and strong muscles, MRC 
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grades below 4 were classified as ‘weak’, and MRC 4-5 were classified as ‘strong’. 
For correlation studies, MRC 4- was designated as 3.5 and 4+ as 4.5.  
 
Nerve conduction studies   
One non-diabetic DM1 patient had an asymptomatic mild sensory neuropathy. 
None of the 3 diabetic patients had neuropathy. 
  
Short exercise test 
The results of the SETs at room temperature are detailed in Table 1.  The SET 
performed on the day of the muscle excitability studies was suggestive of chloride 
channel myotonia in 13 DM1 patients and 1 DM2 patient, and showed a normal 
pattern without significant decrement in the other patients. It was omitted in 1 DM1 
patient. 
 
Velocity recovery cycles 
The results of the MVRCs with 1 and 5 conditioning stimuli are illustrated in 
Figure 1A and B, respectively, and the measurements are compared in Table 2.   
The overlap of the MVRCs following single stimuli in Fig. 1A suggest that 
resting potentials are similar in the 3 groups, and this is supported by the similar 
values of relative refractory period (MRRP) in Table 2.  MRRP is affected by 
temperature
33
, so it is important to note that skin temperatures overlying the muscle 
were closely matched between groups (NC: 29.9°C ± 1.2; DM1: 30.0 ± 1.3; DM2: 
30.4 ± 0.6).   
In both DM1 and DM2 patients, there was an increase in the residual 
supernormality to multiple conditioning stimuli, similar to that observed in patients 
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with myotonia congenita (MC) 
27
, and attributable to impaired chloride conductance.  
Fig 1D shows that this highly significant abnormality was present equally in the 
stronger and weaker DM1 patients.   
Although the later parts of the recovery cycles after 5 conditioning impulses 
were very similar in DM1 and DM2 patients (Fig. 1B) and were qualitatively similar 
to the MC patients, the earlier parts diverged.  At 20 ms, the MC patients showed a 
substantial increase in supernormality compared with controls, the DM2 patients 
showed only a trend in this direction, and the DM1 patients showed a significant 
decrease (Table 2).  Fig. 1C shows that this contrasting behavior to the MC patients 
was primarily attributable to the weaker DM1 patients. 
Fig. 2 shows more clearly the separation of DM1 and MC patients and normal 
controls by the 2 MVRC measures used in Fig. 1C and D.  The possibility that the 
difference between DM1 and MC patients may relate to sodium channel availability is 
suggested by the comparison with the MC patients taking sodium channel blockers, as 
against those not on treatment.  
Frequency Ramp 
The effects of increasing the stimulation rate from an average of 1 Hz to 15 Hz 
(i.e. 30 Hz for 1s with an interval of 1s) for patients and controls are listed in Table 3.  
The responses of the weaker DM1 patients to the frequency ramp, illustrated in Fig. 3, 
differed from all the other groups. The responses to the first stimulus in each 1 sec 
train (i.e. after a 1 sec recovery period from the last train) did not differ significantly 
in latency from the controls during the frequency ramp.  After the end of the 
frequency ramp, however, when the stimulation rate had reverted to once every 2 sec, 
the latencies of the weaker DM1 patients took much longer to recover (Fig. 3B).  The 
time taken for the mean latency to recover to its value before the ramp was 8.4s in the 
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controls, but 47s in the weak DM1 group.  Fig. 3D shows that, of all the groups 
tested, only the latencies of the weaker DM1 patients had failed to recover 30 sec after 
the end of the ramp.  Fig. 3E shows how this measurement was strongly related to 
strength, as assessed by MRC grade.  In DM1 patients, strength was negatively 
correlated with age (ρ = -0.63, P=0.0052), but not as strongly as with Lat(30Hz+30s) 
(ρ = 0.75, P = 0.00038).  There was no significant correlation between MRC grade 
and decrement on the short exercise test (ρ = 0.061, P = 0.80), or with the CTG 
expansion size (ρ = 0.25, P = 0.56).  
 
DISCUSSION 
 In this study we used a direct muscle stimulation paradigm to investigate the 
muscle membrane properties in patients with DM1 and DM2, and compared the 
findings against normal controls and with those we obtained previously using the 
same stimulation protocol in MC patients. Here we discuss the similarities and 
differences between the groups, and the insights they give into chloride channels and 
sodium transport in the DM1 and DM2 patient groups. 
Comparisons between MVRC recordings in DM1, DM2, and MC patients 
Changes in residual supernormality attributed to reduced chloride conductance. 
The most striking and consistent abnormality in the recovery cycles of the DM 
patients was the slow return to baseline latency after 5 conditioning stimuli (Fig. 1B), 
which was assessed by the residual supernormality, 950 ms after 5 conditioning 
stimuli (5XRSN) (Fig. 1D, Table 3).  This was very similar to our finding in MC 
patients
27
 and presumably reflects the well-established reduction in chloride 
conductance in DM1
9,11
 and DM2
26
. As in the case of the MC patients, the reduced 
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chloride conductance had little effect on the recovery cycle following a single 
conditioning impulse (Fig. 1A), because chloride channels only make a major 
contribution to muscle membrane conductance when the fibers become depolarized. 
Significance of changes in early supernormality. 
Although the late components of the recovery cycles are similar for DM1, 
DM2, and MC patients, the early parts show clear differences.  While the DM2 
patients resembled the MC patients in having an increased early supernormality 
(SN20, 5SN20) compared with controls, this was not the case with the DM1 patients 
who, by contrast, showed a reduced early supernormality (Fig. 1B), mostly due to the 
weaker DM1 patients (Fig. 1C, Table 3). In the MC patients, the increased early 
supernormality was attributed to an increased depolarizing afterpotential related to the 
reduced chloride conductance
27
. In the DM2 patients, the tendency towards increased 
early supernormality was therefore consistent with the reduction in chloride 
conductance. So what was the explanation for the opposite change in early 
supernormality seen in the weak DM1 patients?  Apart from the chloride conductance, 
the amplitude of the depolarizing afterpotential and related supernormality depends on 
the balance between inward sodium and outward potassium charge movements during 
the action potential, and there are 2 reasons why sodium channel currents may be 
reduced. 
One possibility, suggested by comparison with the MC patients taking sodium 
channel blockers (Fig. 2), is that sodium channel availability was reduced in the DM1 
patients.  In this case medication could not be responsible, since only 1 of our DM1 
patients (and none of the weaker ones) was taking a sodium channel blocker (Table 
1). It has been known for some time that DMPK itself has a role in modulating 
skeletal sodium channels. In 2000, Mounsey et al
12
 described a 50% reduction in peak 
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Na
+ 
current amplitude in both DMPK
-/-
 and DMPK 
+/-
 mouse myocytes
12
 which is not 
due to a reduction in Na
+
 channel expression but is thought to be related to silencing 
of muscle sodium channels
34
. A second possibility is that a deficiency in sodium 
pumping results in both depolarization of the resting membrane potential and a raised 
intracellular sodium concentration ([Na
+
]i) (see below), both of which would act to 
reduce inward sodium currents during the action potential. Membrane depolarization 
would normally be expected to prolong muscle relative refractory period, but a 
reduction in sodium currents due to a reduced sodium gradient may have a contrary 
effect, so that our observation that MRRP was not significantly prolonged in DM1 
(Table 2) does not rule out this second possibility. 
 
Frequency Ramp changes and the sodium pump 
In patients as in normal controls, latencies decreased progressively as 
stimulation rate was increased and then started to increase again (Fig. 3), probably 
because the progressive depolarization due to potassium accumulation in the t-tubules 
inactivates sodium channels.  At the end of the frequency ramp, when the stimulation 
rate returned to 0.5 Hz, the latency of the controls recovered within a few seconds to 
its pre-ramp value, and then overshot the mark and continued at a slightly higher level 
for the rest of the recording.  The rapid recovery and overshoot are probably due to 
activation and sensitization of the sodium pump to [Na
+
]i by the impulse train.  
Buchanan et al (2002)
35
 found that in rat skeletal muscle, sodium pump activity is 
increased up to 20-fold by short trains of impulses (e.g. 60 Hz for 10s), so that after a 
brief increase [Na
+
]i is actually reduced. In contrast, when [Na
+
]i was increased by 
electroporation or the ionophore monensin, sodium pump activity was increased much 
less, and [Na
+
]i recovered more slowly and without undershoot. The rapid pump 
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response to impulse trains is apparently driven not by the increase in [Na
+
]i, but by 
release from sensory nerve endings of CGRP, which via cAMP, protein kinase A, and 
a small auxiliary protein phospholemman, causes an increase in the affinity of the 
Na
+
/K
+
-ATPase for [Na
+
]i 
35,36
.  The much slower than normal recovery from the 
frequency ramp in the weak DM1 patients (Fig. 3B), indicates that the pump is not 
activated in the normal way, perhaps because of a deficiency in this rapid response 
mechanism.  A weaker response of the sodium pump to muscle activation in DM1 was 
previously indicated by a much greater than normal release of potassium ions into the 
circulation following a brief period of exercise 
37
.  Perhaps also relevant to our finding 
of a strong correlation between latency recovery after the frequency ramp and muscle 
strength (Fig. 3E: ρ = 0.75, P < 0.001), a similarly strong correlation between muscle 
strength and 
3
H-ouabain binding sites has been found in biopsied vastus lateralis from 
DM1 patients (r = 0.60, P < 0.001)
38
.  It therefore seems likely that latency recovery 
after the frequency ramp provides an index of sodium pump dysfunction in DM1 and 
that our results reinforce the evidence of an association between weakness in DM1 
and sodium pump dysfunction. 
A correlation between weakness and sodium pump dysfunction could occur: 
(a) because the weakness results in downregulation of the pump; (b) because the 
pump dysfunction causes weakness; or (c) because both are caused by a third factor.  
There is evidence for both (a) and (b), which may mutually reinforce each other.  
Clausen
39
 reviewed the abundant evidence that training leads to an upregulation and 
inactivity to a downregulation of muscle sodium pumps, and the correlation between 
muscle sodium pump content and muscle strength found in DM1 patients by 
Andersen et al.
38
 was attributed to inactivity.  On the other hand, weakness due to 
amyotrophic lateral sclerosis and peripheral neuropathy was associated with an 
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increase, rather than a decrease in pump sites
40
,  and the abnormal release of 
potassium into the circulation after brief exercise was peculiar to myotonic 
dystrophy
37
.  This likely indication of pump dysfunction was not found in 88 patients 
with a variety of neuromuscular disorders, nor in 4 patients with limb girdle or Becker 
muscular dystrophy.  A plausible reason why the pump response to exercise should be 
reduced in DM1, but not in DM2 or other neuromuscular disorders, is that 
phospholemman is a substrate for DMPK
41
  and phospholemman is involved in the 
acute regulation of the Na
+
/K
+
-ATPase response to exercise in human skeletal muscle 
42
.   
DM1 is a progressive multi-systemic disorder that resembles in many respects 
premature aging
43
.  The weakness is associated with muscle atrophy and cannot be 
accounted for simply by sodium pump dysfunction, leading us to option (c) above, 
that the correlation is due to a common causal factor.  The progressive nature of DM1 
is most likely explained by the fact that the CTG repeat number is not stable but tends 
to increase throughout life and to increase differently in different tissues
44,45
.  The 
mechanism of CTG repeat expansion appears to be due to misguided attempts by 
DNA repair mechanisms to correct inappropriate conformations due to an existing 
repeat.  The paradoxical consequence of this is that cells with the most active DNA 
repair mechanisms, such as muscle stem cells (satellite cells) are the most prone to 
expand their repeats until they can no longer support regeneration, and muscle 
degeneration ensues
43
 . The correlation we observed between weakness and slow 
recovery from the frequency ramp (Fig. 3) may therefore simply reflect a common 
dependence on the progressive increase in CTG repeat number with age.  CTG repeat 
number correlates inversely with DMPK mRNA and protein
13
 , and DMPK deficiency 
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is expected, via phospholemman, to reduce the rapid response of the sodium pump to 
muscle activation.  
 In conclusion, we have found that MVRCs in DM1 and DM2 patients provide 
evidence of a delayed repolarization after short trains of muscle action potentials, 
similar to that seen in MC patients, and attributable to a reduction in chloride 
conductance.  The slow recovery after the 1-minute frequency ramp, which was 
strongly related to weakness in the DM1 patients, is most likely an indication of a 
reduced ability of the sodium pump to restore ionic gradients in these patients.   
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Table 1. 
 
Pt Diagnosis Gene †Size of CTG 
expansion 
(DM1) 
Gender Age TA Power 
(MRC 1-5) 
SET  
(%) 
1 DM1 DMPK medium W 29 5 28 
2 DM1 DMPK medium W 25 5 77 
3 DM1 DMPK NA W 32 3 26 
4 DM1 DMPK medium M 20 4 12 
5 DM1 DMPK small M 57 5 10 
6 DM1 DMPK medium to large M 49 2 46 
7 DM1 DMPK small W 73 2 10 
8 DM1 DMPK NA M 57 1 21 
9 DM1 DMPK medium M 43 4 20 
10 DM1 DMPK NA W 32 5 20 
11 DM1 DMPK large W 45 3 35 
12 DM1 DMPK NA M 29 5 37 
13 DM1 DMPK NA W 48 4- * 1 
14 DM1 DMPK medium W 20 5 6 
15 DM1 DMPK NA M 30 5 35 
16 DM1 DMPK NA M 59 2 33 
17 DM1 DMPK NA W 54 4- *  
18 DM1 DMPK NA W 44 4+ * 22 
19 DM2 CNBP NA W 41 5 6.5 
20 DM2 CNBP NA W 67 5 15 
21 DM2 CNBP NA W 57 5 0 
22 DM2 CNBP NA M 38 5 1 
23 DM2 CNBP NA W 62 5 9 
 
*MRC 4- plotted as ‘3.5’, and 4+ as ‘4.5’ for correlations.  
† Size of CTG repeats -  small: 100-200 repeats, medium: 200-700 repeats, large: 
>700 repeats. NA= Not available, because the confirmation of the pathological 
expansion was made using triplet-repeat primed PCR (DM1) or quadruple-repeat 
primed PCR (DM2), in which no estimation of expansion size is given.  
Only patient 14 was on a sodium channel blocker (carbamazepine). 
Page 26 of 32
John Wiley & Sons, Inc.
Muscle & Nerve
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
 2727 
Table 2. Velocity Recovery Cycle measurements compared between groups. 
 
 
NC (n=20) DM1 (n=18) 
DM1 wk 
(n=8) 
DM2 (n=5) 
MRRP (ms) 
3.96 ± 1.07 
3.85 ± 0.84 
P = 0.81 
4.13 ± 1.10 
P = 0.30 
3.78 ± 0.60 
P = 1.0 
ESN (%)  
11.1 ± 2.7 
9.8 ± 2.5 
P = 0.14 
8.6 ± 2.5 
P = 0.025 
12.4 ± 5.1 
P = 0.82 
ESN@(ms) 
8.5 ± 1.9 
8.5 ± 1.7 
P = 0.59 
8.9 ± 2.1 
P = 0.50 
8.2 ± 1.0 
P = 0.77 
5ESN (%) 
13.0 ± 3.5 
10.9 ± 2.8 
P = 0.059 
9.7 ± 3.3 
P = 0.025 
14.7 ± 3.6 
P = 0.45 
SN20 (%) 
6.6 ± 1.5 
6.5 ± 1.5 
P = 0.98 
5.7 ± 0.9 
P = 0.23 
8.1 ± 2.7 
P = 0.28 
5SN20 (%) 
12.5 ± 2.9 
10.3 ± 2.7 
P = 0.017 
9.0 ± 3.2 
P = 0.0068 
13.6 ± 2.2 
P = 0.53 
LSN (%) 
3.7 ± 0.9 
3.5 ± 0.9 
P = 0.41 
3.0 ± 0.8 
P = 0.089 
4.2 ± 1.2 
P = 0.53 
RSN (%) 
0.17 ± 0.20 
0.12 ± 0.28 
P = 0.97 
0.09 ± 0.37 
P = 0.64 
0.13 ± 0.40 
P = 0.87 
5XLSN (%) 
7.3 ± 1.7 
7.0 ± 1.8 
P = 0.55 
7.0 ± 2.0 
P = 0.75 
8.3 ± 1.1 
P = 0.30 
5XRSN (%) 
0.98 ± 0.36 
2.37 ± 0.99 
P = 0.00000021 
2.27 ± 1.08 
P = 0.00039 
2.25 ± 0.85 
P = 0.0023 
 
The first column shows values obtained from the tibialis anterior muscle in 20 normal 
control subjects (NC). Columns 2 and 4 show values obtained from the DM1 and 
DM2 patients. Column 3 shows values from the subset of the 8 DM1 patients in 
whom the tibialis anterior was weak (MRC grades <4). P values are for comparisons 
with the normal control group. Significant P values of <0.01 are highlighted. 
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Table 3. Frequency Ramp  measurements compared between groups. 
 
 
NC (n=20) DM1 (n=18) DM1 wk (n=8) DM2 (n=5) 
Lat(15Hz)Last% 84.5 ± 3.8 
84.2 ± 4.4 
P = 0.56 
83,0 ± 4.4 
P = 0.31 
84.6 ± 9.0 
P = 0.37 
Lat(15Hz)First%              93.5 ± 3.1 
93.4 ± 3.9 
P = 0.87 
93.3 ± 3.2 
P = 0.94 
93.5 ± 1.6 
P = 0.68 
Lat(30Hz) First %              94.6 ± 4.0 
94.6 ± 5.4 
P = 0.87 
94.2 ± 6.3 
P = 0.55 
94.9 ± 2.3 
P = 1.0 
Lat(30Hz+30s)%           101.7 ± 1.7 
100.6 ± 2.9 
P = 0.26 
98.4 ± 2.4 
P = 0.000061 
101.4 ± 2.3 
P = 0.78 
 
Effects of frequency ramp on latencies of muscle action potentials. Values given are 
mean ± SD, P values are for the Mann Whitney U test. Significant P values of <0.01 
are highlighted. 
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Figure legends 
Figure 1.  Muscle velocity recovery cycles following 1 and 5 conditioning impulses. 
Mean changes in latency with time after single conditioning impulse (A) and 5 
conditioning impules (B) for 3 groups superimposed: grey line = 20 NC, filled circles 
= 18 DM1, filled triangles = 5 DM2.  C:  Latency changes for 5 different groups 20 
ms after 5 conditioning impulse, with the DM1 group separated into stronger (10s) 
and weaker (8w) subgroups.  Boxes indicate interquartile ranges, and lines indicate 
median values.  Comparisons with NC group by Mann Whitney U test indicated as 
NS = P>0.05, * = P<0.05, ** P<0.01, *** = P<0.001, **** = P < 0.0001, ***** = 
P<0.00001.   D: Similar plots for residual supernormality, 900-1000 ms after 5 
conditioning stimuli. Arrows in B indicate times of measurements in C and D.  
Figure 2.  Effect of sodium channel blockers on MVRCs in myotonia congenita. 
Scatter plots of 4 groups, comparing early and late  supernormality changes as in Fig. 
1C and D, between NC, DM1, and MC patients not on medication (MC
a
), and MC 
patients being treated with sodium channel blockers (MC
b
). 
Figure 3.  Effects of frequency ramp on velocities of muscle action potentials.  Left 
hand column shows latency changes from baseline stimulation (0.5 Hz) to first stimuli 
in 1 sec trains, that increased from 1 to 30 Hz, and recovery when stimulation reverted 
to 0.5 Hz.  Grey lines: mean of NC group.  Black circles: mean values for stronger 
DM1 patients (A), weaker DM1 patients (B), and DM2 patients (C).  D: Latency 
changes 30 sec after end of frequency ramp for 5 groups plotted as in Fig. 1C; **** = 
P<0.0001.  E:  Correlation between latency changes 30 sec after frequency ramp and 
muscle strength according to MRC scale, for 18 DM1 patients; *** = P<0.001. 
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Figure 2.  Effect of sodium channel blockers on MVRCs in myotonia congenita. Scatter plots of 4 groups, 
comparing early  and late  supernormality changes as in Fig. 1C and 1D, between NC, DM1 and MC patients 
not on medication (MCa), and MC patients being treated with sodium channel blockers (MCb).  
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